Paper Details

  1. Home
  2. Paper Details

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.

Author: GibbsMegan A, KleinCheri E, MostafaNael M, NaderAhmed, NgJuki W, NoertersheuserPeter, PolepallyAkshanth R, ShebleyMohamad, WinzenborgInsa

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Elagolix is an effective treatment for endometriosis pain, with a well-understood pharmacologic profile. This abstract describes the clinical pharmacology and pharmacokinetics of elagolix, showing its effectiveness and providing information on dosing regimens and interactions with other medications.
Paper Details　
Original Abstract of the Article :
The clinical pharmacology of elagolix was extensively evaluated in clinical studies in healthy subjects and in women with endometriosis. Elagolix pharmacokinetics (PK) show significant population variability, however they are minimally affected by patients' baseline characteristics and demographics,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051932/

データ提供：米国国立医学図書館（NLM）

Elagolix: A New Frontier in Oral Gonadotropin-Releasing Hormone Receptor Antagonist Therapy for Endometriosis

Endometriosis, a painful and debilitating condition characterized by the growth of endometrial tissue outside the uterus, significantly impacts the lives of millions of women. While various treatments are available, including hormonal therapy, there is a need for new and effective options with improved tolerability and convenience.

Elagolix: A Promising Oral Treatment for Endometriosis Pain

Elagolix, an oral gonadotropin-releasing hormone receptor antagonist, has emerged as a promising new treatment for endometriosis-related pain. This research explores the clinical pharmacology of elagolix, providing a comprehensive overview of its pharmacokinetic and pharmacodynamic properties, including its mechanism of action, efficacy, and safety profile.

Understanding the Efficacy and Safety of Elagolix in Endometriosis

The research highlights the efficacy of elagolix in reducing endometriosis pain, demonstrating its ability to suppress gonadotropin and ovarian hormones. The study also addresses potential interactions with other medications and provides guidance on dosing based on individual patient characteristics. This information is critical for clinicians to make informed decisions regarding elagolix treatment for endometriosis.

Dr. Camel's Conclusion

Just as a camel navigates the challenging desert landscape, women with endometriosis must navigate the complexities of their condition. Elagolix represents a significant advancement in the treatment of endometriosis, offering a convenient and effective oral option to alleviate pain and improve quality of life.

Date :
  1. Date Completed 2021-05-26
  2. Date Revised 2023-11-03
Further Info :

Pubmed ID

31749075

DOI: Digital Object Identifier

PMC7051932

Related Literature

Article Analysis
・Effects of elagolix
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.